The current status of minimal residual disease assessment in myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Bone marrow transplantation · 2017
   Trial
2. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Article
3. Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens.Saudi journal of biological sciences · 2022
   Article
4. A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?Clinical case reports · 2019
   Article
5. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.Frontiers in oncology · 2019
   Review
6. Chromothripsis in Treatment Resistance in Multiple Myeloma.Genomics & informatics · 2017
   Article
7. MMSA-1 expression pattern in multiple myeloma and its clinical significance.Clinical and experimental medicine · 2016
   Article
8. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.Cancer immunology research · 2015
   Article
9. Single-molecule analysis reveals widespread structural variation in multiple myeloma.Proceedings of the National Academy of Sciences of the United States of America · 2015
   Article
10. New criteria for response assessment: role of minimal residual disease in multiple myeloma.Blood · 2015
    Review
11. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Leukemia · 2014
    Article

Corrections and comments

• Comment on
  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as